ArticleJHEP reports : innovation in hepatology2026
Time-restricted eating, liver health, and fecal microbiota in adults with overweight or obesity: A randomized controlled trial.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05310721 (Efficacy and Feasibility of Time-restricted Eating on Cardiometabolic Health in Adults With Overweight/Obesity), which is not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Feasibility of Time-restricted Eating on Cardiometabolic Health in Adults With Overweight/Obesity: The EXTREME Study
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Time-restricted eating and gut microbiota alpha diversity in adults with overweight or obesity: an updated rapid systematic review.Frontiers in nutrition · 2026Pooled it
- Intermittent Fasting and the Gut Microbiota: Mechanisms Linking Microbial Remodeling to Metabolic and Immune Regulation.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsThe optimal eating window for time-restricted eating (TRE) remains unclear. We investigated the effects of 8-h TRE combined with usual care (UC, a Mediterranean diet-based education program) vs. UC alone over 12 weeks on hepatic fat fraction (HFF), liver health markers, and fecal microbiota in adults with overweight or obesity.
methodsIn this multicenter randomized trial, participants (50% women) were assigned to UC (n = 49), early TRE (n = 49), late TRE (n = 52), or self-selected TRE (n = 47) group. HFF was assessed by magnetic resonance imaging; liver markers included elastography-based parameters, liver enzymes, and circulating biomarkers. Fecal microbiota was analyzed by 16S rRNA gene sequencing.
resultsHFF decreased significantly within the three TRE groups (all p ≤0.02). However, there were no between-group differences when comparing early TRE (mean difference [MD] -0.4%, p = 0.95), late TRE (MD -1.5%, p = 0.15), and self-selected TRE groups (MD -0.7%, p = 0.77) with the UC group, or among the TRE groups themselves (all p ≥0.41). Similarly, there were no between-group differences in liver health markers and fecal microbiota. Participants with metabolic dysfunction-associated steatotic liver disease at baseline as well as those achieving ≥5% weight loss had greater reductions in HFF than those who did not (MD -2.7 and -2.6%, respectively; both p <0.001). A higher proportion of participants in the TRE groups achieved ≥5% weight loss compared with UC (41-44% vs. 16%, p = 0.001).
conclusionsThese findings suggest that the timing of the eating window in time-restricted eating may not impact HFF or microbiota composition beyond the effects of weight loss; however, the study was not powered for secondary outcomes. IMPACT AND IMPLICATIONS: Time-restricted eating (TRE) is increasingly used for obesity management, but whether the timing of the eating window influences liver health remains unclear. In this 12-week multicenter randomized trial, adding early, late, or self-selected 8-h TRE to Mediterranean diet-based usual care led to within-group reductions in MRI-assessed hepatic fat fraction (HFF); however, it did not confer greater improvements in HFF, liver health markers, or fecal microbiota than usual care alone. Participants with baseline metabolic dysfunction-associated steatotic liver disease (MASLD) and those achieving ≥5% weight loss experienced larger reductions in HFF, suggesting that these reductions in this context are more closely linked to weight loss and baseline steatosis than to eating window timing. Clinically, these findings support prioritizing feasible eating schedules and strategies that help patients attain clinically meaningful weight loss, particularly among individuals with MASLD. CLINICAL
trial registrationThe study is registered at ClinicalTrials.gov (NCT05310721).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.